Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283319 · ClinicalTrials.gov registry record · Phase 2
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
A Phase 2 study, sponsored by Biomedical Advanced Research and Development Authority.
- Completed
- Registry status
- Phase 2
- Development phase
- 366
- Enrollment target
NCT03283319 is a Phase 2 study that has completed, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 366 participants.
The verdict
NCT03283319, a Phase 2 study, has completed, sponsored by Biomedical Advanced Research and Development Authority.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 366 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days. Three different antigen dose levels of Panblok H7 will be tested.
Interventions
- BIOLOGICAL MF59
- BIOLOGICAL 3.75 ug Panblok H7
- BIOLOGICAL 7.5 ug Panblok H7
- BIOLOGICAL 15 ug Panblok H7
- BIOLOGICAL AS03
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2018-11-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283319
The ClinicalTrials.gov registry entry for NCT03283319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomedical Advanced Research and Development Authority, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MF59 is the first listed.
NCT03283319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283319 about?
NCT03283319 is a clinical study titled "Panblok H7 Vaccine Adjuvanted With AS03 or MF59". The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days. Three different antigen dose levels of Panblok H7 will be tested.
What is the current status of trial NCT03283319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 366 participants. The study started on 2017-09-20. Estimated completion is 2018-11-09.
What interventions are being tested in trial NCT03283319?
The interventions under investigation include: MF59 (BIOLOGICAL), 3.75 ug Panblok H7 (BIOLOGICAL), 7.5 ug Panblok H7 (BIOLOGICAL), 15 ug Panblok H7 (BIOLOGICAL), AS03 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03283319?
This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.